ARG007 Shows Significant Neuroprotection in Concussion Study
Filed with ASX · · 5 pages · English
Summary by 6ix AI
The study demonstrated that a single low dose of xaranetide significantly reduced neuroinflammation, oxidative stress, and axonal damage in a repeated mild traumatic brain injury model. These findings suggest that xaranetide may modify the biological response to concussion rather than just alleviating symptoms, reinforcing its potential as a disease-modifying therapy.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Argenica Therapeutics Ltd on 6ix
Story so far
Earlier from Argenica Therapeutics
- ARG007 (Xaranetide) Completes All Three FDA Requested Assays
- WHO Confirms Xaranetide as INN for ARG-007
- IND Application Advanced With Successful Completion of Assay
- Clinical Advisory Committee Established to Advance Phase 2b
- Presentations at European Stroke Organisation Conference
Later from Argenica Therapeutics
- Appendix 4E & Annual Report to 30 June 2026
- New Mechanism Findings Offer Insights Into Phase 2 Signal
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics